Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to
evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor
effects of ALRN-6924 alone or in combination with cytarabine in patients with
relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with
wild-type (WT) TP53